Stockbabie NewsFatherMarketNewsMarket Intelligence
MARKETS
Wire · Markets
Markets

Moleculin Reports 43% And 36% Complete Remission Rates In Annamycin Phase 2/3 Trial For Relapsed Or Refractory AML

Nov 4, 2026 · 11:04 AM ET· updated 1h ago

First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AMLMoleculin Biotech, Inc. (NASDAQ:MBRX) ("Moleculin" or the "Company")

Share
Why It Matters

Moleculin's new cancer medicine showed strong results in early testing. Watch if the company can repeat these results in more patients.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
MBRX8.30
-0.02 (-0.24%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.